<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The clinical trial, Japan <z:chebi fb="0" ids="35664">Statin</z:chebi> Treatment Against Recurrent <z:hpo ids='HP_0001297'>Stroke</z:hpo> (J-STARS), is being carried out to investigate the efficacy of <z:chebi fb="0" ids="35664">statin</z:chebi> treatment against recurrent <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>To participate in J-STARS, patients must have a past history of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> excluding cardioembolic events, and must be clinically diagnosed with <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Before starting J-STARS, we needed to be aware of the clinical characteristics of the patients who were eligible to participate in this study </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Between 1999 and 2002, 7,149 patients with <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> were enrolled in a <z:hpo ids='HP_0001297'>stroke</z:hpo> data bank developed by the Japan Standard <z:hpo ids='HP_0001297'>Stroke</z:hpo> Registry Study Group </plain></SENT>
<SENT sid="4" pm="."><plain>From this, we acquired the data on 1,487 patients with first-ever atherothrombotic infarction (ATI) or <z:e sem="disease" ids="C0333559" disease_type="Disease or Syndrome" abbrv="">lacunar infarction</z:e> (LI) with a satisfactory functional outcome on discharge </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> were significantly younger (65.3+/-11.0 vs 68.4+/-10.9, p&lt;0.0001) and showed a higher frequency of concomitant <z:hpo ids='HP_0000822'>hypertension</z:hpo> (70.9% vs 61.0%, p=0.0002), <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (42.2% vs 25.7%, p&lt;0.0001) or both (31.7% vs 16.4%, p&lt;0.0001) compared to those without <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The ratio of ATI to LI and the frequency of prior <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e>) did not differ between the 2 groups </plain></SENT>
<SENT sid="7" pm="."><plain>Among 467 patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>, 52.7% did not receive treatment on admission </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: ATI or LI patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> had an earlier <z:hpo ids='HP_0011007'>age of onset</z:hpo> and higher frequency of other lifestyle-related diseases, and this probably includes many with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, whereas the frequency of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e> was not different between these 2 groups </plain></SENT>
</text></document>